John Murphy, M.D., MPH, DPH, President COVID-19 Long-haul Foundation<\/p>\n\n\n\n
Persistent, debilitating fatigue and exertional intolerance are among the most frequent and disabling features of post-acute sequelae of SARS-CoV-2 infection (PASC, \u201clong-COVID\u201d). Accumulating evidence implicates multi-level bioenergetic dysfunction \u2014 from altered systemic metabolism and metabolomics profiles to impaired mitochondrial respiration in immune and other peripheral cells \u2014 as a core contributor to the symptom cluster commonly labelled \u201cexhaustion.\u201d This article synthesizes current evidence for mechanisms linking SARS-CoV-2 infection to sustained energy depletion, integrates findings from long-COVID and myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS) literature, and outlines diagnostic approaches, clinical features, and therapeutic implications. We review viral persistence, autoimmunity, endothelial and microvascular pathology, immune-mediated metabolic reprogramming, mitochondrial damage, redox imbalance, and their intersections with neuroinflammation and autonomic dysfunction. We emphasize heterogeneity across patient subgroups and the need for standardized bioenergetic assays and multi-omic phenotyping to advance diagnostics and therapeutics. Nature+2PMC+2<\/a><\/p>\n\n\n\n Long-COVID; PASC; fatigue; mitochondrial dysfunction; energy metabolism; immunometabolism; myalgic encephalomyelitis; post-infectious fatigue. Nature<\/a><\/p>\n\n\n\n SARS-CoV-2 infection has produced a substantial global burden of persistent symptoms in a subset of survivors, collectively termed long-COVID or PASC. Fatigue, post-exertional malaise (PEM), cognitive dysfunction (\u201cbrain fog\u201d), orthostatic intolerance and exercise intolerance are among the most frequently reported complaints, often lasting months to years and impairing quality of life. Epidemiologic and mechanistic work suggests several overlapping pathophysiologic pathways, with energy metabolism emerging as a central axis linking immune activation, endothelial dysfunction, and neuronal symptoms. Recent comprehensive reviews and multi-omic studies have highlighted mitochondrial and metabolic signatures in long-COVID cohorts. Nature+2PMC+2<\/a><\/p>\n\n\n\n Large cohorts and systematic characterizations show that a notable minority of SARS-CoV-2 infected individuals develop prolonged fatigue and related syndromes. Estimates vary by case definition, cohort, variant era and vaccination status. Several reports suggest that between ~5\u201315% of infected individuals experience persistent symptoms at months post infection in many cohorts, with fatigue among the top complaints (exact prevalence varies). Long-COVID is heterogeneous; symptom clusters have been identified (e.g., cardiopulmonary, neurocognitive, musculoskeletal) and fatigue often co-occurs with cognitive symptoms and autonomic complaints. The Guardian+2TIME+2<\/a><\/p>\n\n\n\n Clinical phenotype of exhaustion:<\/strong> The core features relevant to energy depletion are: (1) persistent, disproportionate physical and mental fatigue; (2) post-exertional symptom exacerbation (PEM) with delayed recovery; (3) reduced exercise tolerance and rapid fatigability; (4) cognitive complaints and sleep disturbance; (5) orthostatic intolerance in many patients. These phenotypes overlap substantially with ME\/CFS and other post-infectious fatigue states. Cell+1<\/a><\/p>\n\n\n\n Multiple, non-mutually exclusive mechanisms are proposed. Evidence supports contributions from (A) persistent viral antigens or low-level replication; (B) sustained immune activation and cytokine signaling; (C) autoantibodies and post-infectious autoimmunity; (D) endothelial and microvascular dysfunction including microthrombi; (E) direct mitochondrial perturbation and altered cellular metabolism; and (F) neuroimmune and autonomic dysregulation. These mechanisms interact to produce an energy crisis at the cellular and systemic level. PMC+2Nature+2<\/a><\/p>\n\n\n\n Several studies detect viral RNA, proteins, or antigenic fragments persisting in tissues (gut, lymphoid tissue, olfactory mucosa) months after acute infection in subsets of patients; persistent antigenic stimulation could sustain local and systemic inflammation and metabolic rewiring. While direct causal proof linking tissue persistence to fatigue is incomplete, the concept of antigen persistence as a driver of chronic immune activation and metabolic consequences is plausible and supported by immunologic profiling studies. PMC+1<\/a><\/p>\n\n\n\n Protracted cytokine and interferon signaling (for example, persistently elevated IFN-\u03b3 in some cohorts) has been reported and associates with fatigue and muscle symptoms in selected studies. Chronic cytokine exposure can induce metabolic shifts (Warburg-like glycolytic shift in immune cells), reduce mitochondrial oxidative phosphorylation capacity, and increase reactive oxygen species (ROS), all contributing to decreased efficiency of ATP generation. Financial Times+1<\/a><\/p>\n\n\n\n Autoantibodies directed at neural or autonomic targets, G-protein coupled receptors, or endothelial components have been reported in both ME\/CFS and long-COVID cohorts; these may produce dysautonomia, microvascular dysfunction, and altered perfusion to muscles and brain, thereby reducing oxygen delivery and exacerbating energetic deficits. The autoimmunity hypothesis remains under investigation and may explain a subset of patients. Cell+1<\/a><\/p>\n\n\n\n Endothelial activation, microclots, and microvascular dysregulation have been proposed as contributors to tissue hypoperfusion and impaired oxygen delivery in long-COVID. Microvascular dysfunction can amplify energetic stress by limiting oxygen and substrate delivery necessary for mitochondrial ATP production. Nature+1<\/a><\/p>\n\n\n\n SARS-CoV-2 viral proteins interact with host mitochondrial pathways in vitro, and multiple clinical studies report signatures consistent with mitochondrial dysfunction in PBMCs and plasma metabolomics in long-COVID patients (impaired oxidative phosphorylation, altered lipid metabolism, reduced glutathione, altered amino acid metabolites). These data suggest that mitochondrial impairment\u2014whether from direct viral interaction, immune-mediated damage, oxidative stress, or mitochondrial-nuclear communication failure\u2014plays a central role in energy depletion. PMC+2ScienceDirect+2<\/a><\/p>\n\n\n\n Mitochondria generate ATP via oxidative phosphorylation (OXPHOS) coupling substrate oxidation to a proton gradient and ATP synthase activity. The balance between OXPHOS and glycolysis, mitochondrial membrane potential (\u0394\u03a8m), reactive oxygen species (ROS) generation, and mitochondrial dynamics (fusion\/fission, mitophagy) determine cellular energy competence. Disruption at any of these nodes can manifest as reduced ATP availability, early fatigue with exertion, and impaired recovery. ScienceDirect<\/a><\/p>\n\n\n\n Activated immune cells reprogram metabolism (e.g., increased glycolysis, reduced spare respiratory capacity in mitochondria) to support effector functions. Chronic, low-grade immune activation \u2014 as documented in subsets of long-COVID patients \u2014 can divert systemic energy substrates, increase resting metabolic demands, and reduce physiological reserve for muscular or cognitive tasks, producing subjective and objective fatigue. OUP Academic+1<\/a><\/p>\n\n\n\n Sustained inflammation produces ROS and reactive nitrogen species; chronic oxidative stress damages mitochondrial DNA, lipids, and proteins, impairing electron transport chain function. Several studies show altered antioxidant status (e.g., glutathione) in PASC cohorts, suggesting oxidative injury as a mediator of mitochondrial impairment. Frontiers+1<\/a><\/p>\n\n\n\n Autonomic dysfunction (orthostatic intolerance, postural tachycardia) and endothelial abnormalities can reduce perfusion to skeletal muscle and brain during activity, producing mismatch between energy demand and oxygen\/substrate supply; this mismatch manifests clinically as rapid fatigability and PEM. Microvascular dysfunction also impairs substrate exchange even when global metrics (blood pressure) are normal. Nature<\/a><\/p>\n\n\n\n Assays of peripheral blood mononuclear cells (PBMCs) from long-COVID patients show reduced mitochondrial respiration, lower maximal respiratory capacity, and altered coupling efficiency in several cohorts. Proteomic and metabolomic plasma studies reveal signatures of impaired fatty-acid oxidation, altered amino-acid metabolism, and markers consistent with oxidative stress. These peripheral signatures can correlate with symptom severity in some studies. ScienceDirect+2PMC+2<\/a><\/p>\n\n\n\n Exercise testing in subsets of patients reveals reduced peak VO\u2082, early anaerobic threshold, and abnormal recovery kinetics, often reflecting impaired peripheral oxygen utilization rather than isolated deconditioning in many cases. Muscle biopsies remain limited but have shown mitochondrial abnormalities in some post-infectious fatigue syndromes; more systematic muscle histology in long-COVID is needed. The Lancet+1<\/a><\/p>\n\n\n\n Neuroimaging studies in COVID survivors indicate changes in gray matter volume and functional connectivity in some cohorts, and neuroinflammation is proposed as a mechanism for cognitive fatigue. Neuroimmune activation can alter cerebral energy metabolism and neurotransmitter pathways, compounding peripheral energy deficits. Le Monde.fr+1<\/a><\/p>\n\n\n\n No single diagnostic biomarker for long-COVID fatigue is validated. However, a multi-modal approach improves characterization:<\/p>\n\n\n\n Key load-bearing findings (supported across multiple cohorts): PBMC mitochondrial respiratory deficits, plasma metabolomic signatures of impaired fatty-acid oxidation and altered amino-acid profiles, and persistent immunologic signatures in some patients (e.g., elevated IFN-\u03b3). ScienceDirect+2PMC+2<\/a><\/p>\n\n\n\n There is substantial phenotypic and mechanistic overlap between long-COVID fatigue and ME\/CFS, including PEM, cognitive dysfunction, autonomic symptoms, and evidence of mitochondrial\/energetic abnormality in many studies. Lessons from ME\/CFS research (heterogeneity, need for standardized outcome measures, multi-omic phenotyping) apply directly to long-COVID. However, long-COVID cohorts also present unique immunologic and vascular features linked to the specific biology of SARS-CoV-2. Comparative studies are essential to delineate shared vs disease-specific mechanisms. Science+1<\/a><\/p>\n\n\n\n No approved disease-modifying therapy specifically targets long-COVID fatigue; approaches are currently symptomatic, rehabilitative, or investigational. Therapeutic strategies under study or proposed include:<\/p>\n\n\n\n Overall, the heterogeneity of mechanisms suggests precision medicine approaches guided by biomarker subtyping will be required to identify effective interventions. The Lancet<\/a><\/p>\n\n\n\n To progress from description to mechanism-driven therapy, key priorities include:<\/p>\n\n\n\n Energy depletion in long-COVID appears to be a multi-factorial syndrome arising from the interplay of persistent immune activation, autoimmunity, endothelial and microvascular dysfunction, and direct or indirect mitochondrial impairment. Peripheral signals \u2014 including PBMC respiratory deficits and plasma metabolomic changes \u2014 provide convergent evidence for impaired oxidative metabolism in many patients. The heterogeneity of findings mandates a precision approach that combines robust clinical phenotyping with multi-omic and functional bioenergetic assays to stratify patients and guide targeted interventions. A research agenda prioritizing longitudinal cohorts, mechanistic trials, and harmonized testing will be essential to translate mechanistic insights into effective treatments for exhaustion in long-COVID. ScienceDirect+2Nature+2<\/a><\/p>\n\n\n\n Because this manuscript synthesizes many contemporary studies, below I list the most salient, recent peer-reviewed works and reviews cited in the text. For submission, I can convert these into any required journal format (e.g., Nature, Science) and expand the reference list to include 25+ full primary studies and reviews (I already used 25+ sources in composing the manuscript and can present them formatted with DOIs).<\/p>\n<\/blockquote>\n\n\n\n John Murphy, M.D., MPH, DPH, President COVID-19 Long-haul Foundation Abstract Persistent, debilitating fatigue and exertional intolerance are among the most frequent and disabling features of post-acute sequelae of SARS-CoV-2 infection […]<\/p>\n","protected":false},"author":2,"featured_media":14144,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1368,1321,84,106,168,169,1361,862,1366,1298,325,1367],"tags":[],"class_list":["post-14141","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-chalder-fatigue-scale","category-chronic-fatigue","category-chronic-fatigue-syndrome","category-cytokine-storm","category-fatigue","category-fatigure","category-ifn-","category-malaise-fatigue","category-mitochondrial-depletion","category-mitochondrial-dysfunction","category-mitochondrial-effects","category-oxydative-stress"],"_links":{"self":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/14141","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14141"}],"version-history":[{"count":2,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/14141\/revisions"}],"predecessor-version":[{"id":14143,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/14141\/revisions\/14143"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/media\/14144"}],"wp:attachment":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14141"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14141"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Keywords<\/h2>\n\n\n\n
\n\n\n\n1. Introduction<\/h2>\n\n\n\n
\n\n\n\n2. Epidemiology and clinical scope of exhaustion in long-COVID<\/h2>\n\n\n\n
\n\n\n\n3. Proposed etiologies linking SARS-CoV-2 to sustained energy depletion<\/h2>\n\n\n\n
3.1 Viral persistence and antigen reservoirs<\/h3>\n\n\n\n
3.2 Chronic immune activation and cytokine signaling<\/h3>\n\n\n\n
3.3 Autoimmunity and pathogenic autoantibodies<\/h3>\n\n\n\n
3.4 Endothelial, microvascular and coagulation abnormalities<\/h3>\n\n\n\n
3.5 Direct mitochondrial insults and metabolic reprogramming<\/h3>\n\n\n\n
\n\n\n\n4. Cellular and systems-level physiology of energy depletion<\/h2>\n\n\n\n
4.1 Mitochondrial bioenergetics: basic principles<\/h3>\n\n\n\n
4.2 Immunometabolism and the metabolic cost of immune activation<\/h3>\n\n\n\n
4.3 Oxidative stress and antioxidant depletion<\/h3>\n\n\n\n
4.4 Vascular and autonomic contributions to impaired energy delivery<\/h3>\n\n\n\n
\n\n\n\n5. Pathology and tissue-level observations<\/h2>\n\n\n\n
5.1 Blood and immune cell findings<\/h3>\n\n\n\n
5.2 Muscle and exercise physiology<\/h3>\n\n\n\n
5.3 Central nervous system and neuroinflammatory findings<\/h3>\n\n\n\n
\n\n\n\n6. Clinical diagnostic parameters and biomarkers<\/h2>\n\n\n\n
\n
Post Type: “Post”<\/h1>\n\n\n
\n\n\n\n7. Differential diagnosis: ME\/CFS and other post-infectious syndromes<\/h2>\n\n\n\n
\n\n\n\n8. Therapeutic implications and interventions<\/h2>\n\n\n\n
\n
\n\n\n\n9. Research gaps and priorities<\/h2>\n\n\n\n
\n
\n\n\n\n10. Conclusions<\/h2>\n\n\n\n
\n\n\n\nSelected references <\/h2>\n\n\n\n
\n
\n